The article reviews metabolic‑associated fatty liver disease (MASLD), its link to insulin resistance and heart disease, and how primary‑care providers can spot it early using simple blood‑based scores and ultrasound‑based stiffness tests. It highlights that the drug resmetirom is now FDA‑approved for certain liver fibrosis cases, and notes that semaglutide is being studied as a possible future treatment for early‑stage disease, but no detailed results are given yet.
Peng. Qing Q; Hao. Liyuan L; Li. Shenghao S; Yu. Fei F; Li. Na N; Hu. Xiaoyu X
This review says that while drugs like semaglutide can help fatty liver disease, they often cause stomach problems and don’t work well on scar tissue. Natural compounds from plants and traditional medicines might improve liver health by fixing bile‑acid balance and gut microbes, but most studies are in animals and human data are mixed. More solid human trials are needed before these can be recommended as reliable treatments.
The review says that a type of cell death called ferroptosis makes brain damage worse after a bleed in the brain, and that some drugs, including the diabetes drug semaglutide, might block this process and protect neurons. However, the evidence is still early and comes from lab studies, not human trials, so it isn’t ready to be turned into a DIY health protocol.
Bonnesen. Kasper K; Heide-Jørgensen. Uffe U; Christensen. Diana H DH; Lash. Timothy L TL; Peder...
A large Danish study compared two GLP‑1 drugs—semaglutide and dulaglutide—in people with type 2 diabetes and found that after three years their rates of major heart problems were almost the same. The tiny difference seen (‑0.2% absolute risk) was not statistically meaningful.
Maher. Clare B CB; Guo. Brad B; Dunlop. Anthony A AA
A 43‑year‑old woman developed eye inflammation (optic neuritis and scleritis) about a month after starting semaglutide. Tests ruled out other autoimmune causes, and steroids cleared the problem in three months. The report suggests semaglutide might, in rare cases, trigger inflammatory eye issues.
Deng. Zhaobin Z; Zheng. Dongxu D; Son. Jinsook J; Du. Wen W; McKimpson. Wendy M WM; Liu. Qingli Q; A...
In a mouse model of type‑2 diabetes, both semaglutide and tirzepatide lowered blood sugar after four weeks, but they did not stop the mice from gaining weight (semaglutide) or restore the health of insulin‑producing beta cells. The drugs didn’t reverse early signs that beta cells were losing their identity, and they actually left more beta cells with low PDX1, a key maturity marker.
Decker. Sérgio R R SRR; Chaudhary. Richard S RS; Inoue. Kosuke K; Song. Yang Y; Ndumele. Chiadi...
In 2023, only about 5% of older Medicare patients with type 2 diabetes started using the weight‑loss drugs semaglutide or tirzepatide. People who are Black, have both Medicare and Medicaid, or live in poorer neighborhoods were less likely to begin these treatments.
Dhippayom. Teerapon T; Meraz. Manuel M; Lee. Haeseon H; Hur. Chin C; Inadomi. John M JM; Veettil. Sa...
A review of economic studies found that weight‑loss drugs like semaglutide and liraglutide usually aren’t worth the price for treating obesity in people without diabetes, at least in high‑income countries, though they might pay off for some groups over a very long time.
The paper talks about the moral questions around using weight‑loss drugs like Ozempic and Mounjaro, pointing out both the health perks and the possible social problems, but it doesn’t give any new tips on how to use them.
Videbæk. Nicoline N; Jørgensen. Louise L; de Lemos Rieper. Carina C; Hummelshøj. Lone...
Scientists made lab tests that can spot antibodies that block semaglutide (a weight‑loss/diabetes drug) and natural GLP‑1 more easily and even when the drug is present. They tweaked the test conditions, sample handling, and control antibodies to get better detection limits.
Brenisin. Kristina K; Kinnafick. Florence F; King. James J; Millard. Louise L; Arya. Donna D; Hodgso...
This paper describes a planned pilot study that will give people on antipsychotic meds, who are very overweight, weekly injections of semaglutide (the weight‑loss drug Wegovy) plus a lifestyle program, to see if it helps them lose weight in a secure mental‑health facility. No results are reported yet, so it’s mainly a description of what researchers intend to do.
Zou. Toujun T; Wan. Juan J; Liao. Rufang R; Bai. Lan L; Li. Xinyan X; Cheng. Xu X; Zhou. Junjie J; T...
Scientists discovered a new nanoparticle called QF70 that can break down a protein involved in fat storage in liver cells and improve fatty liver, obesity, and insulin resistance in mouse studies, but it has nothing to do with semaglutide use in people.
Sillassen. Christina Dam Bjerregaard CDB; Faltermeier. Pascal P; Petersen. Johanne Juul JJ; Kamp. Ca...
This paper only outlines a plan to review existing trials of GLP‑1 drugs like semaglutide, tirzepatide and liraglutide for heart‑related outcomes; it does not present any new data or recommendations.